Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

British Journal of Cancer

Volumn 89, Issue 3, 2003, Pages 577-584

  Geoerger, B ^a   Grill, J ^a   Opolon, P ^a   Morizet, J ^a   Aubert, G ^a   Lecluse, Y ^a   Van Beusechem, V W ^b   Gerritsen, W R ^b   Kirn, D H ^c,d   Vassal, G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ONYX PHARMACEUTICALS   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenoviral cytolysis; Brain tumour; Radiosensitization; Xenografts

Indexed keywords

ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53; RADIOSENSITIZING AGENT; VIRUS VACCINE;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT FAILURE; TUMOR GROWTH; TUMOR REGRESSION; VIRUS INFECTIVITY; VIRUS REPLICATION; WHOLE BODY RADIATION; XENOGRAFT; ANIMAL; CELL DEATH; EXPERIMENTAL NEOPLASM; FEMALE; GENE THERAPY; GENETICS; GLIOMA; MOUSE; NUDE MOUSE; PATHOLOGY; VIROLOGY;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CELL DEATH; FEMALE; GENE THERAPY; GLIOMA; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; VIRAL VACCINES;

EID: 0042477562     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601102     Document Type: Article

References (22)

1. Barker DD, Berk AJ (1987) Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156: 107-121
2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323
3. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC (2001) CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 61: 5453-5460
4. Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427-1433
5. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G (2002) Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62: 764-772
6. Goodrum FD, Ornelles DA (1998) p53 Status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection. J Virol 72: 9479-9490
7. Heise C, Lemmon M, Kirn D (2000) Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 6: 4908-4914
8. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645
9. Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 97: 6242-6244
10. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69: 236-240
11. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885
12. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7: 535-545
13. Martin-Duque P, Sanchez-Prieto R, Romero J, Martinez-Lamparero A, Cebrian-Sagarriga S, Guinea-Viniegra J, Dominguez C, Lleonart M, Cano A, Quintanilla M, Ramon YC (1999) In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. Int J Oncol 15: 1163-1168
14. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60: 1193-1196
15. Sanchez-Prieto R, Lleonart M, Cajal S (1995) Lack of correlation between p53 protein level and sensitivity of DNA-damaging agents in keratinocytes carrying adenovirus E1a mutants. Oncogene 11: 675-682
16. Sanchez-Prieto R, Quintanilla M, Cano A, Leonart ML, Martin P, Anaya A, Cajal S (1996) Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 13: 1083-1092
17. Sanchez-Prieto R, Quintanilla M, Martin P, Lleonart M, Cano A, Dotto GP, Cajal S (1998) In vivo antitumor effect of retrovirus-mediated gene transfer of the adenovirus E1a gene. Cancer Gene Ther 5: 215-224
18. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356
19. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652
20. Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS (1999) p53 Selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 59: 4369-4374
21. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Second Edition). Br J Cancer 77: 1-10
22. You L, Yang CT, Jablons DM (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 60: 1009-1013